ARTICLE | Company News
Dr. Reddy's gets green light to market opioid dependence generic
November 30, 2018 6:27 PM UTC
Dr. Reddy's Laboratories Ltd. (NYSE:RDY) said on Nov. 20 that a U.S. federal court vacated a district court's preliminary decision that prohibited the company from selling its generic version of film Suboxone buprenorphine/naloxone sublingual from Indivior plc (LSE:INDV). Dr. Reddy's said it will "resume its launch activities as soon as permitted."
The Court of Appeals for the Federal Circuit concluded that Indivior was unlikely to succeed in its patent infringement case, according to Dr. Reddy's...